Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eiger Biopharma (EIGR)

Eiger Biopharma (EIGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Eiger BioPharma: Q3 Earnings Snapshot

Eiger BioPharma: Q3 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Stocks Tread Water Before the Open as U.S. Inflation Data Looms

September S&P 500 futures (ESU23) are down -0.02%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.04% this morning as market participants geared up for a key U.S. consumer inflation report...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
ORCL : 115.34 (+0.22%)
AAP : 76.53 (-1.88%)
AAPL : 169.02 (+1.27%)
WRK : 47.48 (+0.81%)
AV-.LN : 465.400 (-1.13%)
WKHS : 0.1607 (-0.12%)
RCKT : 23.63 (-0.17%)
F : 12.95 (+0.08%)
SQSP : 35.69 (-1.71%)
EIGR : 1.7250 (-9.21%)
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharma: Q2 Earnings Snapshot

Eiger BioPharma: Q2 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharma: Q1 Earnings Snapshot

Eiger BioPharma: Q1 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar